Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Sees Large Decline in Short Interest

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the recipient of a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 2,300 shares, a decrease of 88.7% from the November 30th total of 20,400 shares. Based on an average daily trading volume, of 198,200 shares, the short-interest ratio is currently 0.0 days.

Chugai Pharmaceutical Stock Performance

Shares of OTCMKTS:CHGCY traded up $0.49 during trading on Friday, hitting $22.50. The company’s stock had a trading volume of 72,339 shares, compared to its average volume of 126,908. The company has a market capitalization of $74.05 billion, a PE ratio of 28.85 and a beta of 0.82. Chugai Pharmaceutical has a fifty-two week low of $14.52 and a fifty-two week high of $26.00. The business has a 50 day moving average price of $22.47 and a two-hundred day moving average price of $21.74.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.